Financial Data and Key Metrics Changes - The company achieved record quarterly revenues of $7.2 million for Q2 2024, representing a 53% increase compared to $4.7 million in Q2 2023 [12] - Gross margin for Q2 2024 was 73%, slightly down from 74% in the same period last year [12] - Operating income improved to $2 million, an increase of $1.1 million year-on-year [12] - Net income for Q2 2024 was $6.6 million, a significant turnaround from a net loss of $7.3 million in Q2 2023 [12] - Adjusted EBITDA rose to $1.5 million from $171,000 in the same quarter last year [13] Business Line Data and Key Metrics Changes - Revenue from the Ultomir systems increased by 47% year-on-year, with 788 active systems in the field at the end of Q2 2024 [7] - Revenue from the Ultamist product line grew by 62% year-on-year [7] - Consumable applicators revenue surged by 67% year-on-year and 15% sequentially from Q1 2024 [7][8] Market Data and Key Metrics Changes - The company is focusing on building a robust pipeline of large and midsized customers in the wound care space, particularly in skilled nursing and long-term care [10] - The company has already sold more systems in Q3 2024 than in all of Q3 2023, indicating strong market traction [10] Company Strategy and Development Direction - The company aims for rapid profitable growth and has increased its revenue growth guidance for Q3 2024 to 65-75% year-on-year [6][7] - The termination of the merger with SEPA was deemed necessary as it no longer served the best interests of shareholders [14] - The company is simplifying its capital structure, including a planned reverse stock split to reduce share count and improve shareholder equity [16][17] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's improved fundamentals and the potential for a breakout year in 2024 [17] - The focus is on being valued for the business rather than the capital structure, with plans for increased outreach to investors once the stock price is more respectable [30] Other Important Information - The company paid off long-standing debt liabilities, adding over $8 million to stockholders' equity [12] - Operating expenses increased to $3.2 million in Q2 2024, but as a percentage of revenue, they dropped to 62% from 73% in Q2 2023 [12] Q&A Session Summary Question: Can we talk about actual numbers and acquisition units or new customers? - Management did not disclose exact average selling prices but mentioned that the list price for an Ultramist system is about $35,000, and they are capturing more of it than before [20][21] Question: How is the company generating more sales in the current environment? - Management indicated that improving the capital structure is essential for enhancing the company's valuation and attracting more investors [29][30]

Sanuwave Health (SNWV) Q1 2024 Earnings Call May 10, 2024 08:30 AM ET Speaker0 Please note that this call is being recorded, and I will be standing by should you need any assistance. It is now my pleasure to turn the conference over to Morgan Frank. Please go ahead. Speaker1 Thank you very much. Hi, everyone, and welcome to TANUWAVE's first quarter twenty twenty four earnings call. As many of you probably saw, our Form 10 Q was filed with the SEC Thursday night, and our earnings release was issued this morn ...